SHIPPEO
22.5.2023 17:46:25 CEST | Business Wire | Press release
Shippeo, a global leader in real-time multimodal transportation visibility, today announced it has been recognized in the Gartner® Magic Quadrant™ for Real-time Transportation Visibility Platforms.
“I am pleased to see many of Shippeo’s recognitions over the past 12 months reflected, we believe, in our positioning in this year’s Magic Quadrant,” says Shippeo co-founder and COO, Lucien Besse.
Shippeo has a 95% willingness to recommend rating on Gartner Peer Insights™, receiving the overall rating of 4.8/5*. “These are highly important metrics for us, and reassure us that we are providing our customers with the best value, and delivering what we promise,” says Besse, adding “we believe this high customer satisfaction was helped by the fact we are the only provider to offer a triple SLA, which contractually guarantees rapid carrier onboarding, high tracking rates, and high ETA accuracy, as well as the tremendous progress we have made across all aspects of our business over the last 12 months.”
The company recently raised a record $50m in fundraising, with all existing investors taking part. “This fundraising round is the largest ever for a supply chain visibility software in Europe,” explains Besse. “It will help us bolster our sound financial position for many years to come, and accelerate our ongoing North American and APAC expansion, while giving customers and partners confidence in the longevity potential of our partnerships with the strong path to profitability we’ve laid out as a company.”
Existing investors taking part included Battery Ventures, Partech, NGP Capital, ETF Partners, Bpifrance Digital Venture and SAP.io. Notable new strategic investors include Hong Kong-based LFX Venture Partners and Japan-based Yamaha Motor Ventures, whose investment is helping to ramp up operations across Asia-Pacific, as well as Orlen VC, based in Poland, and Shift4good, a global VC fund dedicated to impact investing in smart mobility and circular economy businesses.
An expert in sustainability, Shift4good strictly invests in companies with the potential to move the needle on climate change. Beyond a strong belief in the company’s business potential, Shift4Good’s decision to invest was driven by the potential of Shippeo’s new Carbon Visibility solution to have a positive impact across the transportation and logistics sector. The emissions calculator, now generally available to all customers, combines Shippeo’s advanced visibility data capabilities with cutting edge data modeling from industry expert Searoutes, to provide extremely accurate transport and distribution GHG (CO2e) emissions reporting. The tool offers users GLEC-accredited CO2 equivalent emissions calculations, without the need to manually consolidate data supplied by carriers.
Continued expansion into North America and APAC was boosted by a new global partnership with e2open, offering Shippeo’s native real-time in-transit visibility within their comprehensive global supply chain management platform.
The company also recently welcomed some of the most iconic brands in the world, including Amazon, Barilla (US), Epson, Geodis, Jacob Douwe Egberts (JDE), Jaguar Land Rover, Lassonde, L'Oréal, Moët Hennessy (LVMH), SABIC International (the second largest public company in the Middle East) and Siemens Energy.
Over the last year, Shippeo’s team grew to more than 230 Shippians, including senior executive and SaaS veteran Philippe Vanhove as new Chief Revenue Officer, who brings 25 years of experience in scaling fast-growing, international SaaS organizations, having managed multinational sales operations, marketing, lead generation, human resources, and finance.
In April, the company launched a new biannual platform release cycle, delivering its latest Spring platform release. New and enhanced features across all transport modes introduced to users improve the platform experience and enhance visibility data quality. Highlights include a new Shippeo berth ETA as part of their Ocean Visibility offering, which is significantly more accurate and reliable than the ones received from ocean carriers, as well as new vessel AIS-based milestone detection for more accurate milestones at ports during loading, unloading and transshipment. A swathe of usability enhancements throughout the multimodal visibility platform include new container delay filters, carrier TMS tag synchronization, and configurable notifications to help users manage shipments more efficiently, by exception.
2022 also saw the launch of Shippeo’s Carrier Recognition Program, celebrating over 400 of the world’s most exceptional carriers, who provide the best service to shippers with consistently high levels of shipment tracking. The company also held their inaugural Visibility Star Awards last November, which recognize the efforts our carrier community has made to provide great service to their clients, and celebrate their exceptional commitment to real-time visibility.
*Disclaimer:
* Gartner Disclaimer: based on 214 reviews as of May 18 2023 in the Real-Time Transportation Visibility Platforms market.
Gartner “Magic Quadrant for Real-Time Transportation Visibility Platforms 2023” by Carly West, Oscar Sanchez Duran, and Nathan Lease, 16 May 2023.
GARTNER is a registered trademark and service mark of Gartner, Inc. and/or its affiliates in the U.S. and internationally, MAGIC QUADRANT and PEER INSIGHTS are registered trademarks of Gartner, Inc. and/or its affiliates and are used herein with permission. All rights reserved.
Gartner does not endorse any vendor, product or service depicted in its research publications and does not advise technology users to select only those vendors with the highest ratings or other designation. Gartner research publications consist of the opinions of Gartner’s research organization and should not be construed as statements of fact. Gartner disclaims all warranties, expressed or implied, with respect to this research, including any warranties of merchantability or fitness for a particular purpose.
Gartner Peer Insights content consists of the opinions of individual end users based on their own experiences with the vendors listed on the platform, should not be construed as statements of fact, nor do they represent the views of Gartner or its affiliates. Gartner does not endorse any vendor, product or service depicted in this content nor makes any warranties, expressed or implied, with respect to this content, about its accuracy or completeness, including any warranties of merchantability or fitness for a particular purpose.
About Shippeo
Shippeo is a global leader in real-time multimodal transportation visibility, helping major shippers and logistics service providers operate more collaborative, automated, sustainable, profitable, and customer-centric supply chains. This is made possible with highly accurate, real-time operational visibility and perfect workflow orchestration. Their Multimodal Visibility Network integrates with more than 1,000 TMS, telematics and ELD systems, enabling Shippeo’s platform to provide instant access to real-time shipment tracking across all transport modes, in a single portal, through an intuitive user experience. A proprietary and industry-leading machine learning algorithm offers unmatched ETA accuracy, allowing supply chain companies to quickly anticipate problems, proactively alert customers, efficiently manage exceptions with collaborative workflows, and accurately measure CO2 and GHG emissions from supply chain transport. Hundreds of customers, including global brands like Coca-Cola HBC, Carrefour, Renault Group, Schneider Electric, Total, Siemens Energy, Faurecia, Saint-Gobain and Eckes Granini, trust Shippeo to track more than 32 million shipments per year across 110 countries. Learn more at www.shippeo.com
LinkedIn, Facebook, Twitter
About Shift4Good
Shift4Good is a venture capital fund manager dedicated to impact investing in smart mobility & circular economy start-ups. With teams based in both Paris and Singapore, Shift4Good mostly focus on European and Southeast Asian opportunities. Shift4Good can deploy between €0.5m and €20m per company and mostly invest in Series A and Series B rounds and can allocate 10% of their funds to pre-Series A rounds. More information: https://www.shift4good.com/
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230519005162/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Ningbo FEED Meeting Confirms Full Confidence in Q1 2027 FID for Allied Biofuels’ US$6.1 Billion Presidential Decree-Backed SAF and e-SAF Project18.9.2026 17:38:00 CEST | Press release
Allied Biofuels has held a major Front-End Engineering Design (FEED) meeting at Sinopec’s office in Ningbo, China, bringing together Allied Biofuels, Sinopec Engineering Group Co., Ltd. of China, Topsoe A/S of Denmark, Sasol South Africa Limited, and Plug Power of the United States — the principal international engineering and technology providers supporting its US$6.1 billion Presidential Decree-backed Sustainable Aviation Fuel (SAF) and e-SAF project in Uzbekistan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918708077/en/ FEED Meeting - Ningbo, China At the joint FEED meeting of the project’s core engineering and technology stakeholders, the discussions established clear alignment on engineering responsibilities, technology interfaces, design deliverables, project integration and the coordinated execution programme required to advance the project through FEED. All stakeholders working on the project expressed full co
Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli® (Relacorilant)18.9.2026 14:00:00 CEST | Press release
Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth
Enhertu® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 14:00:00 CEST | Press release
Recommendation based on DESTINY-Breast05 phase 3 trial results that showed Enhertu reduced the risk of invasive disease recurrence or death by 53% versus T-DM1 Daiichi Sankyo and AstraZeneca’s Enhertu has the potential to become a new standard of care in this early breast cancer setting Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at th
CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 12:58:00 CEST | Press release
The information contained within this press release is for the purpose of scientific exchange.It is intended for scientific, financial and investor media only.If approved, Jyselecawill be indicated for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy.Despite the availability of multiple treatment options, nearly half of people living with axSpA do not respond adequately to current therapies, and just 10-20% reach inactive disease within 16-24 weeks of initiating treatment.CHMP’s positive opinion is based on findings from the OLINGUITO Phase 3 study, where improvements in the signs and symptoms of axSpA with filgotinib were observed early and maintained over 52 weeks of treatment.Jyselecais already approved in Europe and the United Kingdom, for the treatment of moderate to severe rheumatoid arthritis and ulcerative colitis. Alfasigma S.p.A, a global
IMPACT Therapeutics and Pharmanovia Announce Positive CHMP Opinion for Senaparib, as a Potential First-Line Maintenance Treatment of Advanced High-Grade Epithelial Ovarian, Fallopian Tube, and Primary Peritoneal Cancer18.9.2026 12:38:00 CEST | Press release
For business and medical media only This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918325771/en/ Stephan Eder, CEO, Pharmanovia IMPACT Therapeutics (07630.HK), a commercial-stage biotechnology company focused on the discovery and development of targeted anti-cancer therapeutics based on synthetic lethality mechanisms, together with global specialty pharmaceutical company Pharmanovia, today jointly announce that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion recommending the granting of a Marketing Authorisation (MA) for the medicinal product Sepalna® (senaparib) intended for the maintenance treatment of advance epithelial ovarian, fallopian tube and primary peritoneal cancer. Following the CHMP’s recommendation for approval, senaparib will be submitted to the European Commission (EC) for final decision. Once approved by the EC, senaparib will
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom